- €49.21bn
- €48.90bn
- €7.74bn
Brief: UCB's Kygevvi Approved In The EU As First And Only Treatment For Thymidine Kinase 2 Deficiency
Brief: UCB Presents New Bimzelx Data At AAD
Brief: UCB Says Got Positive CHMP Opinion For New Zilbrysq Pre-Filled Pen In EU
Brief: UCB's BIMZELX achieves superiority to SKYRIZI in PsA head-to-head study
Brief: Antengene And UCB Enter Global License Agreement For ATG-201, A CD19/CD3 Bispecific T-Cell Engager For Autoimmune Diseases
UCB shares slip as outlook falls short of expectations
Belgium's UCB 2025 revenue up 26%, beats expectations on strong execution of key products
Brief: UCB Sees 2026 Adj. EBITDA To Grow In High Single-Digit To High Teens Percentage Range At CER
Brief: UCB Says Bimzelx Achieves Inflammotory Lesion Resolution In Be Heard Trials
Brief: UCB Says Its KYGEVVI Recommended For Approval In EU
Live Markets: Mixed reporting season ahead for European pharma
Brief: UCB Reports Positive Results From Gemz Phase 3 Study
European shares on track for weekly gains; US inflation in focus (updated)
UCB soars after Bimzelx-driven 2025 guidance hike
Brief: UCB Upgrades Guidance, Sees 2025 Adj. EBITDA Margin Above 31%
Brief: U.S. FDA Approves Kygevvi® (Doxecitine And Doxribtimine), The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d)
Brief: FDA Approves UCB's Kygevvi
Europe Research Roundup: Caixabank, Nestle, Solaria
UCB shares dip, analyst and company point to prescription data slowdown for BimzelX